PANOVA-3 study showed significant OS improvement with tumor-treating fields plus chemotherapy in pancreatic cancer patients. Median OS was 16.2 months with combination therapy versus 14.16 months with ...

UCLA researchers have developed a CAR-NKT cell therapy that has been more effective than current immunotherapies at fighting ...

CHICAGO -- For the first time in a phase III trial, overall survival (OS) in unresectable pancreatic cancer improved significantly versus chemotherapy with the addition of tumor treating fields ...

High doses of vitamin C could be a new breakthrough in treating cancer. The University of Iowa Health Care Carver College of Medicine has shared results from a randomized, phase 2 trial testing the ...

Video Credit: Weill Cornell Medicine It's not surprising that pancreatic cancer is often referred to as a silent killer. With ...

Atebimetinib combined with modified chemotherapy achieved a 94% six-month overall survival rate in first-line pancreatic cancer patients, surpassing the typical 67% with standard treatment. The ...

Immuneering has reported 94% overall survival (OS) at six months in first-line pancreatic cancer, emboldening the biotech to start planning a pivotal trial to support accelerated approval of its MEK ...

A phase 3 trial found that adding chemoradiotherapy (CRT) after induction chemotherapy in patients with unresectable pancreatic cancer did not extend overall survival compared to chemotherapy alone ...

Actuate Therapeutics has set its sights on getting elraglusib approved for pancreatic cancer after the glycogen synthase kinase‐3 beta (GSK-3β) drug showed a three-month survival increase in a phase 2 ...

November marks Pancreatic Cancer Awareness Month, highlighting one of the third leading causes of cancer deaths in the U.S.

Medical researchers are celebrating after a vaccine is showing promising results in response to pancreatic cancer. Although it’s still in the early trial stage, this one-size-fits-all treatment could ...